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Background: Human papillomavirus (HPV)-positive oropharyngeal cancer (OPSCC) is associated with improved survival compared
with HPV-negative disease. However, a minority of HPV-positive patients have poor prognosis. Currently, there is no generally
accepted strategy for identifying these patients.
Methods: We retrospectively analysed 270 consecutively treated OPSCC patients from three centres for effects of clinical,
pathological, immunological, and molecular features on disease mortality. We used Cox regression to examine associations
between factors and OPSCC death, and developed a prognostic model for 3-year mortality using logistic regression analysis.
Results: Patients with HPV-positive tumours showed improved survival (hazard ratio (HR), 0.33 (0.21–0.53)). High levels of tumour-
infiltrating lymphocytes (TILs) stratified HPV-positive patients into high-risk and low-risk groups (3-year survival; HPV-positive/
TILhigh¼ 96%, HPV-positive/TILlow¼ 59%). Survival of HPV-positive/TILlow patients did not differ from HPV-negative patients (HR,
1.01; P¼ 0.98). We developed a prognostic model for HPV-positive tumours using a ‘training’ cohort from one centre; the
combination of TIL levels, heavy smoking, and T-stage were significant (AUROC¼ 0  87). This model was validated on patients
from the other centres (detection rate 67%; false-positive rate 5.6%; AUROC¼ 0  82).
Interpretation: Our data suggest that an immune response, reflected by TIL levels in the primary tumour, has an important role in
the improved survival seen in most HPV-positive patients, and is relevant for the clinical evaluation of HPV-positive OPSCC.
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Human papillomavirus (HPV) is the primary cause of oropha-
ryngeal cancer (OPSCC), accounting for 40–80% of cases in the
western world (D’Souza et al, 2007; Termine et al, 2008; Adelstein
et al, 2009; Dayyani et al, 2010). The incidence of HPV-associated
OPSCC has increased significantly over the past 40 years, and
continues to rise (Adelstein et al, 2009; Chaturvedi et al, 2011).
HPV-associated OPSCC commonly presents at advanced stage
and is usually poorly differentiated (Adelstein et al, 2009; Sethi
et al, 2012). Although both factors would be expected to result in
poor outcomes, studies report significantly better long-term
survival in most HPV-positive OPSCC patients compared with
those with HPV-negative disease of matched stage (Licitra et al,
2006; Fakhry et al, 2008; Worden et al, 2008; Lassen et al, 2009;
Ang et al, 2010; Dayyani et al, 2010). The explanation for this
remains unclear and may be multifactorial. Human papilloma-
virus-positive tumours have improved response to chemotherapy/
radiotherapy compared with HPV-negative tumours, possibly
modulated through the expression of wild-type p53 and Rb
tumour suppressor genes; patients with HPV-positive cancers have
a lower risk of developing secondary primary tumours, probably
due to the absence of field cancerisation; in addition, HPV status
inversely correlates with biomarkers of poor prognosis such as
EGFR (Westra et al, 2008; Adelstein et al, 2009; Hong et al, 2010a).
A potential explanation for survival benefit may be that tumour-
infiltrating T lymphocytes (TILs), which permeate many HPV-positive
OPSCC, confer a protective effect through an adaptive host immune
response directed against viral antigens, and HPV-16 E7-specific T
cells have been reported in OPSCC patients (Albers et al, 2005;
Wansom et al, 2010, 2012). Although TIL abundance is associated
with improved clinical outcomes in a number of other tumour types,
their role in head and neck malignancy is not well documented (Galon
et al, 2006; Uppaluri et al, 2008; Gooden et al, 2011).
Several studies have reported that the survival advantage of
HPV-driven tumours is independent of treatment modality,
whether surgery, radiation, or chemoradiotherapy (or combina-
tions thereof), raising the possibility that some HPV-positive
patients receive unnecessary treatment (Licitra et al, 2006; Fakhry
et al, 2008; Adelstein et al, 2009; Lassen et al, 2009; Ang et al, 2010;
Hong et al, 2010b). This has led to suggestions that treatment be
de-intensified to reduce therapy-related morbidity (Adelstein et al,
2009), and a number of clinical trials are testing this currently.
However, within the HPV-positive OPSCC population, there
remains a significant minority that respond poorly to treatment
and have a poor prognosis. Ang et al (2010) identified three
different ‘at-risk’ groups for patients with oropharyngeal cancer
and found that HPV-positive patients who were heavy smokers
and had advanced nodal disease (410 pack-years smoking with
N2b disease or above) were at an ‘intermediate’ risk of death. These
factors have subsequently been validated independently and have
been used as exclusion criteria in some de-escalation trials (Ang
et al, 2010; Granata et al, 2012). Other authors have also described
an association between heavy smoking and poor outcome in
patients with HPV-positive tumours (Adelstein et al, 2009; Gillison
et al, 2012; Sethi et al, 2012); however, there is still no widely
accepted strategy for identifying high-risk HPV-positive patients.
In this study, we assess the relative contributions of HPV status and
pathological, molecular, and immunological features in survival from
OPSCC. We correlate them with known clinical predictors of outcome
to formulate a predictive tool for OPSCC patients with the ultimate
aim of facilitating stratification of patients for treatment decisions.
PATIENTS AND METHODS
We retrospectively identified 442 consecutively treated patients
with OPSCC (University Hospital Southampton (UHS; 2000–2010),
n¼ 316; Poole NHS Foundation Trust and Bart’s and the
London NHS Trust (PFT/BLT; 2000–2006), n¼ 126. Patients were
excluded from further analysis if they had follow-up of o6
months, had received either no treatment or treatment without
curative intent, or had an unknown cause of death. Following these
exclusions, 402 patients remained. Archived pathology material
was available for 274 patients who were subsequently analysed
further. Demographics and survival of patients without pathology
material were comparable to those with pathology material
(Supplementary Information). All patients were analysed accord-
ing to REMARK guidelines (McShane et al, 2005). Data were
obtained from patient records on age, sex, site, smoking (non-,
ex- (stopped smoking 46 months previously), light smokers
(defined as o10 pack year history (Ang et al, 2010; Gillison et al,
2012)), heavy smokers (410 pack year history)), alcohol (non-/ex-
drinker, current drinker 410 units per week), T stage, N stage,
treatment modality, treatment failure, tumour recurrence, date,
and cause of death. Data on smoking and alcohol consumption can
be difficult to accurately obtain in retrospective studies, often
because of poor documentation. In this study, smoking data were
more accurately recorded in the medical records than alcohol
consumption, with reliable data available in 87% and 74% of cases,
respectively. Demographics are shown in Table 1. Ethical approval
was obtained (UKCRN 8130; ISRCTN 71276356; and REC
references 09/H0501/90 and 07/Q0405/1).
Treatment. A treatment summary is included in Table 1. The
centres involved in this study differed in their approach to
treatment of OPSCC, with more patients being surgically treated at
UHS. This allowed a direct comparison of survival according to
treatment modality. Patients undergoing chemoradiotherapy
received 2–6 doses of platinum-based chemotherapy (either
cisplatin or carboplatin) combined with 64–66Gy of radiotherapy
given in 32–33 fractions. No patients received accelerated
fractionation or intensity-modulated radiotherapy. Neoadjuvant
chemotherapy was 1-2 doses of either cisplatin or carboplatin, in
conjunction with 5-flurouracil. Of the surgically treated patients,
78% received post-operative radiotherapy. Full details are given in
Supplementary Information.
Histology and immunochemistry. Tumour histology was
reviewed by pathologists (GJT, SJ, and KP) blinded to treatment
and outcome, according to the 1998 UK Royal College of
Pathologist Guidelines, and a suitable paraffin block was selected.
From a haematoxylin/eosin (HþE)-stained section, data were
obtained on grade (well, moderate, or poorly differentiated).
A prominent lymphocytic infiltrate (TIL) was scored under
low-power magnification ( 2  5 objective) as high (diffuse;
present in 480% of tumour/stroma), low (weak/absent; present
in o20% of tumour/stroma), or moderate (patchy; present in
20–80% of tumour/stroma) as described (Marsh et al, 2011).
Concordance between pathologists in identifying TILlow tumours
was 495%. Typical examples of TILhigh and TILlow tumours are
shown in Figure 1D and Supplementary Information.
Tissue microarrays (TMAs) were constructed using triplicate,
randomly selected, paraffin-embedded 1-mm tumour cores
(Aphelys Minicore 2, Mitogen, Harpenden, UK). Automated
immunostaining (Ventana XT, Ventana, Tucson, AZ, USA) was
performed in a CPA-accredited clinical cellular pathology depart-
ment using antibodies optimised to national diagnostic standards
(NEQAS). The antigenic targets were as follows: p16 (CINtec,
Roche, Burgess Hill, UK), EGFR (Dako, Ely, UK), T-lymphocyte
markers (CD3, pan T cells; CD4, helper T cells; CD8, cytotoxic T
cells (all from Novocastra, Milton Keynes, UK); FoxP3, regulatory
T cells (eBioscience, Hatfield, UK), and B lymphocytes (CD20)
(Novocastra). TILs were quantified using a Zeiss AxioCam MRc5
microscope (Zeiss, Cambridge, UK) and Zeiss Axiovision software
(version 4  8  1  0) (Zeiss). An average intratumoural TIL
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Table 1. Baseline characteristics of patients in the retrospective patient cohorts (i.e., at the time of diagnosis)
All OPSCC
n¼274
Number (%)
HPV-positive OPSCC
n¼149
Number (%)
HPV-negative OPSCC
n¼121
Number (%)
Gender
Male 200 (73.0) 111 (74.5) 86 (71.1)
Female 74 (27.0) 38 (25.5) 35 (28.9)
Age at diagnosis (years)
o50 58 (21.2) 40 (26.8) 18 (14.9)
50–69 168 (61.3) 91 (61.1) 74 (61.2)
70þ 48 (17.5) 18 (12.1) 29 (24.0)
Mean (s.d.) 58.2 (11.2) 56.4 (10.8) 60.4 (11.4)
Smoking
Non-/ex-smoker 107 (39.1) 82 (55.0) 23 (19.0)
Current o10 pack-years 18 (6.6) 10 (6.7) 8 (6.6)
Current 410 pack-years 114 (41.6) 41 (27.5) 72 (59.5)
Not Known 35 (12.8) 16 (10.7) 18 (14.9)
Alcohol
Non-/ex-drinker 34 (12.4) 20 (13.4) 14 (11.6)
Current drinker 167 (60.9) 94 (63.1) 72 (59.5)
Not known 73 (26.6) 35 (23.5) 35 (28.9)
Tumour site
Tonsil 158 (57.7) 99 (66.4) 57 (47.1)
Tongue base 70 (25.5) 40 (26.8) 28 (23.1)
Other oropharynx 46 (16.8) 10 (6.7) 36 (29.8)
Median length of follow-up in years (range) 58.0 (8–137) 58.5 (8–137) 57 (8–128)
Disease stage
I/II 53 (19.3) 10 (6.7) 42 (34.7)
III/IV 219 (79.9) 138 (92.6) 78 (64.5)
Not known 2 (0.7) 1 (0.7) 1 (0.8)
T stage
T1/2 187 (68.2) 107 (71.8) 77 (63.6)
T3/4 82 (29.9) 41 (27.5) 41 (33.9)
Not known 5 (1.8) 1 (0.7) 3 (2.5)
Nodal metastases
No 68 (24.8) 15 (10.1) 52 (43.0)
Yes 204 (74.5) 133 (89.3) 68 (56.2)
Not known 2 (0.7) 1 (0.7) 1 (0.8)
N stage
N0–N2a 142 (51.8) 68 (45.6) 73 (60.3)
N2b–N3 130 (47.4) 80 (53.7) 47 (38.8)
Not known 2 (0.7) 1 (0.7) 1 (0.8)
Grade
Well/moderately differentiated 103 (37.6) 34 (22.8) 68 (56.2)
Poorly differentiated 171 (62.4) 115 (77.2) 53 (43.8)
Treatment
Surgery±radiotherapy 117 (42.7) 60 (40.3) 55 (45.5)
Radiotherapy 59 (21.5) 24 (16.1) 34 (28.1)
Chemoradiotherapy 98 (35.8) 65 (43.6) 32 (26.4)
TIL status
Low 79 (28.8) 22 (14.8) 56 (46.3)
Moderate 101 (36.9) 53 (35.6) 46 (38.0)
High 92 (33.6) 72 (48.3) 19 (15.7)
Not known 2 (0.7) 2 (1.3) 0 (0.0)
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score/high-power field ( 400) was calculated across representa-
tive areas of each triplicate core to allow for intratumoural
heterogeneity (i.e., an average of three counts across the tumour).
EGFR and p16 were scored as positive (450% tumour cells
positive) or negative (p50% tumour cells positive).
In situ hybridisation and HPV classification. HPV in situ
hybridisation (ISH) was performed using Genpoint HPV DNA
Probe Cocktail (Dako), which recognises the 13 most prevalent
high-risk HPV genotypes, including HPV-16 and -18. Cases were
scored as negative or positive. Tumours positive both for p16
immunochemistry and HPV ISH were classified as HPV positive
(Robinson et al, 2010).
Microarray data analysis. Affymetrix U133 Plus 2.0 CEL files for
46 HNSCC patient samples (24 survivors and 22 non-survivors)
were downloaded from a publicly available microarray data set
(http://bioinformatics.picr.man.ac.uk/vice/PublicProject.vice?pid=361)
and normalised in BioConductor-R (version 2.15.1) (Bioconductor,
Seattle, WA, USA). Gene-set enrichment analysis was performed
using the GSEA 2.7 software package (Broad Institute of MIT and
Harvard, Cambridge, MA, USA). All 15,031 genes differentially
expressed between survivors and non-survivors were rank ordered
and tested for enrichment of gene sets upregulated during T-cell
differentiation (Best et al, 2013).
Statistics. The primary endpoint was death from OPSCC (i.e.,
disease-specific survival (DSS)). An OPSCC-specific survival time
was measured from the date of diagnosis until date of death from
OPSCC or date last seen alive. For those that died of other causes,
survival from OPSCC was censored at the time of death. Patients in
whom the cause of death was unknown, or who received either no
treatment or treatment with palliative intent, were excluded from
all survival analyses. Kaplan–Meier plots (with log-rank tests) and
both unadjusted and adjusted Cox proportional hazards models
were used to analyse the survival data. Correlations between factors
were assessed by cross-tabulation and the use of either Fisher’s
exact test or w2-test where appropriate.
To evaluate the prognostic performance of each factor (i.e., the
3-year OPSCC death rate), we calculated the detection rate (DR;
also known as sensitivity) and false-positive rate (FPR; also known
as 1 specificity). Detection rate is the proportion of patients who
died from OPSCC with marker-positive results; FPR is the
proportion of patients who did not die from OPSCC with
marker-positive results. Likelihood ratios (DR/FPR) were obtained,
which indicate the strength of a marker (i.e., maximising the DR
while minimising the FPR; Deeks and Altman, 2004).
A prognostic model for 3-year mortality was developed using
binary logistic regression, with a backwards selection procedure
(Royston et al, 2009). Variables were retained in the model if they
were significant at the 5% level. The UHS cohort was used as the
‘training’ set to develop the model, with the PFT/BLT cohort acting
as the ‘validation’ set. A Receiver-operating characteristic (ROC)
curve of the linear predictor was used to identify the optimum cut
point (balancing both sensitivity and specificity; Royston et al,
2009). The prognostic ability of the final model was then assessed
through the calculation of DR and FPR values in the ‘validation’ set
(Heagerty et al, 2000). All statistical tests were two sided and a
P-value of 0.05 was considered significant. Statistical analyses
were performed using SPSS for Windows version 19.0 (IBM,
Portsmouth, UK).
RESULTS
Clinical, pathological, and immunochemical characteristics at the
time of diagnosis are shown in Table 1. Human papillomavirus-
positive tumours were defined as those positive for both p16 and
HPV ISH (Robinson et al, 2010). Similar to previous studies, 94%
of p16-positive cases were HPV ISH positive and 89% of HPV ISH-
positive cases were p16 positive (Robinson et al, 2010).
Of the 274 patients included in the study, 149 (54.4%) were
classified as HPV positive. Human papillomavirus status could not
be established in four cases (insufficient tumour tissue remaining
in the paraffin block); thus, further analysis was performed on 270
patients (median follow-up 58 months and minimum follow-up 8
months). There were 82 deaths from OPSCC over the study period.
Consistent with previous studies, patients with HPV-positive
tumours had significantly improved DSS compared with those
that were HPV negative (Figure 1A; hazard ratio (HR)¼ 0.33
(0.21–0.53)). Table 2A shows the HRs for OPSCC mortality for
each factor separately. Improved survival was significantly
associated with HPV-positive tumours, a younger age at diagnosis,
non-, ex-, or light smokers (defined aso10 pack year history (Ang
et al, 2010; Gillison et al, 2012)), early T-stage tumours (T1/2),
early N-stage tumours (N0–N2a), tumours that were EGFR
negative, and a high level of TILs (assessed on an HþE-stained
section). When a multivariate analysis was performed (adjusting
for age, T stage, N stage, and smoking status), HPV status and TIL
levels remained statistically significant markers of OPSCC
mortality (Table 2A).
In unstratified OPSCC, high TIL levels predicted for survival
(Figure 1C; Table 2A) and correlated significantly with HPV-
positive tumours (Po0.001). The percentage of HPV-positive
patients with high, moderate, and low TIL was 49%, 36%, and
15% respectively (16%, 38%, 46%, respectively, in HPV-
negative tumours). Figure 1D and F show typical examples of
HPV-positive tumours with high and low TIL levels.
Table 1. ( Continued )
All OPSCC
n¼274
Number (%)
HPV-positive OPSCC
n¼149
Number (%)
HPV-negative OPSCC
n¼121
Number (%)
HPV status
Negative 121 (44.2) — —
Positive 149 (54.4) — —
Not known 4 (1.5) — —
EGFR
Negative 108 (39.4) 77 (51.7) 29 (24.0)
Positive 166 (60.6) 72 (48.3) 92 (76.0)
Abbreviations: HPV¼human papillomavirus; OPSCC¼oropharyngeal cancer; TIL¼ tumour-infiltrating lymphocyte.
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Demographics of these groups are shown in Supplementary
Information.
There was a highly significant difference between the
Kaplan–Meier curves for HPV-positive OPSCC DSS according to
TIL levels (Po0.001; Figure 1E); patients with HPV-positive/TILlow
tumours showed similar DSS to HPV-negative patients (Figure 1E)
with an adjusted HR of 1.01 (P¼ 0.98; Table 2A). TIL levels
predicted similarly for progression-free survival (PFS; log-rank
Po0.001; data not shown); patients with HPV-positive/TILlow
tumours also showed similar PFS to HPV-negative patients with an
adjusted HR of 0.64 (P¼ 0.23). The adjusted HRs for HPV-positive
tumours with moderate and high TIL levels indicated a 49% and
79% reduction in OPSCC mortality compared with HPV-negative
tumours (adjusted HRs, 0  51 and 0  21, respectively; P¼ 0.17 and
P¼ 0.02; Table 2B). In HPV-negative tumours, patients with TILhigh
tumours did not show significantly improved survival (adjusted HR,
0.47, P¼ 0.17) over those with TILlow tumours.
Similar to previous studies, we found that heavy smoking
reduced survival benefit in HPV-positive patients (HR, 5.81
(2.38–14.16)). We therefore assessed whether there was an
association between heavy smoking and low TIL levels; low TIL
levels did not correlate with heavy smoking (410 pack-years) and
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Figure 1. Kaplan–Meier curves for OPSCC mortality in combined patient cohorts. (A) Kaplan–Meier curves for OPSCC mortality according to HPV
status (log-rank test, Po0 001). (B) Immunochemistry (p16) and ISH (HPV) showing an example of an HPV-positive tumour. (C) Kaplan–Meier
curves for OPSCC mortality according to abundance of infiltrating lymphocytes (TIL; high, moderate or low; log-rank test, Po0 001). (D) H&E-
stained sections showing examples of OPSCC with high and low TIL infiltrates. Tumour islands are arrowed. In TILhigh tumours, lymphocytes fill the
stromal compartment and infiltrate into tumour islands. (E) Kaplan–Meier curves for OPSCC mortality stratified according to HPV status and TIL
levels. Patients with HPVþ /TILlow tumours show similar survival to HPV-negative patients. (F) Immunochemistry showing typical examples of HPV-
positive OPSCC with high and low TIL. Tumour is positive for p16, T lymphocytes for CD3.
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Table 2A. HRs for disease-specific death from OPSCC
All OPSCC (n¼274)
Univariate
HR (95% CI)
P-value Multivariate HR
a
(95% CI)
P-value
Age
For each additional year 1.02 (1.00–1.04) 0.04 1.03 (1.01–1.05) 0.01
Gender
Female 1 1
Male 1.49 (0.89–2.48) 0.13 1.10 (0.61–1.96) 0.75
Smoking
Non/ex-smoker/current smoker o10 pack-years 1 1
Current smoker 410 pack/years 3.24 (1.94–5.42) o0.001 3.38 (2.01–5.70) o0.001
Drinking
Non/ex-drinker 1 1
Current drinker 0.67 (0.36–1.24) 0.20 0.44 (0.22–0.88) 0.02
Stage
Early (I/II) 1 — —
Late (III/IV) 1.01 (0.58–1.74) 0.98 — —
T stage
T1/2 1 1
T3/4 1.89 (1.21–2.94) 0.005 1.56 (0.95–2.57) 0.08
Nodal metastases
No 1 — —
Yes 1.11 (0.67–1.84) 0.68 — —
N stage
N0–N2a 1 1
N2b–N3 1.68 (1.08–2.60) 0.02 1.75 (1.07–2.86) 0.03
Tumour grade
Well/moderately differentiated 1 1
Poorly differentiated 0.80 (0.52–1.24) 0.31 0.97 (0.59–1.60) 0.90
Treatment
Surgery 1 1
Radiotherapy 1.53 (0.90–2.61) 0.12 1.06 (0.56–2.03) 0.85
Chemoradiotherapy 0.95 (0.57–1.58) 0.83 0.91 (0.51–1.63) 0.74
HPV status
Negative 1 1
Positive 0.33 (0.21–0.53) o0.001 0.45 (0.26–0.79) 0.005
TIL Status
TIL low 1 1
TIL moderate 0.59 (0.37–0.95) 0.03 0.66 (0.39–1.13) 0.13
TIL high 0.21 (0.11–0.41) o0.001 0.28 (0.13–0.62) 0.002
HPV/TIL combined
HPV 1 1
HPVþ /TIL low 0.83 (0.40–1.75) 0.63 1.01 (0.45–2.24) 0.98
HPVþ /TIL moderate 0.41 (0.22–0.78) 0.006 0.49 (0.24–1.01) 0.054
HPVþ /TIL high 0.14 (0.06–0.33) o0.001 0.17 (0.06–0.49) 0.001
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus; HR¼ hazards ratio; OPSCC¼oropharyngeal cancer; TIL¼ tumour-infiltrating lymphocyte.
aMultivariate analysis adjusted for age, T stage, N stage, and smoking status. Patients with no treatment excluded from analysis.
BRITISH JOURNAL OF CANCER Improving outcome prediction in OPSCC
494 www.bjcancer.com |DOI:10.1038/bjc.2013.639
there was no significant difference in the proportion of TILlow
tumours according to the amount smoked (percentage of TILlow
tumours: o10 pack year history 14.1%, 410 pack year history
22.5%, P¼ 0.15).
We performed more complex analysis of the immune infiltrate
to establish whether this improved prognostication in HPV-
positive tumours. We quantified intratumoural T-lymphocyte
number (CD3) and T-cell subsets (CD4, CD8, and Foxp3). We
performed ROC analysis (death from OPSCC at 3 years) to
determine the predictive value of T-cell number and/or subtype,
including subtype ratios (CD4:CD8 and CD8:FoxP3), in compar-
ison with simple HþE evaluation of TIL infiltrate. Immuno-
chemical quantification did not outperform the simpler scoring
method (Figure 2A and B, and Supplementary Information).
To evaluate whether high TIL levels reflected a bystander or
effector response, we tested a publicly available HNSCC microarray
data set (Thurlow et al, 2010) for enrichment of gene sets
defined as upregulated in naive, effector, or memory T cells
(Best et al, 2013). High expression of gene sets associated with
CD8þ T-cell effector function were significantly enriched
(enrichment score (ES)¼ 0.70, P¼ 0.046) in patients with better
survival (Figure 3 and Supplementary Information). Genes
upregulated in naive or late memory CD8þ T cells were
overrepresented in patients with poor survival but at non-
significant levels, possibly reflecting their TILlow status
(ES¼ 0.30, P¼ 0.46; data not shown).
Table 3 shows the prognostic performance of each factor (using
DR and FPR) for predicting 3-year OPSCC mortality in HPV-
positive and HPV-negative patients. Commonly reported prog-
nostic factors are included. In HPV-positive OPSCC, TIL levels
were the best-performing factor, with a likelihood ratio (LR) for
TILlow tumour of 3.3, followed by heavy smoking and advanced
T stage (LR 2.78 and 2.44, respectively). In HPV-negative OPSCC,
advancing age, advanced stage, and poor differentiation were the
predictive factors with the highest LRs (Table 3).
HPV-positive patients had received different types of therapy
(cohorts combined: surgery n¼ 55, chemoradiotherapy n¼ 65,
and radiotherapy n¼ 24). When adjusted for stage and age, there
were no significant treatment-dependent survival benefits (HR for
DSS relative to surgery: radiotherapy 0  76, P¼ 0.79 and
chemoradiotherapy 1  25, P¼ 0.84).
Using the UHS cohort as a training set, we used logistic
regression to develop a predictive model for survival from HPV-
positive OPSCC (at 3 years). The initial variables entered into the
model were as follows: age, T stage, N stage, grade, HPV status,
TIL level, alcohol history, EGFR, and smoking history. The final
model included TIL levels (low vs moderate or high), T stage (T1/2
vs T3/4), and smoking status (heavy vs light-, ex-, or non-smoker).
The regression parameter estimates were used to create a
prognostic score (equation:  4.948þ 2.768 (if a current heavy
smoker)þ 2.310 (if TILlow)þ 2.928 (if T3/4)). ROC analysis was
performed and produced an area under the curve of 0  87
(Figure 4A). A cut-off score of  0.945 was selected based on
this ROC curve (DR, 72.7%; FPR 10.2%; high risk, n¼ 14) and
applied to the PFT/BLT (test; high risk, n¼ 7) cohort. This score
was highly predictive of 3-year mortality, with 66.7% of dead
patients test-positive (DR¼ 67%) and 5.6% of alive patients test-
positive (FPR¼ 5.6%). The resultant LR for prediction of 3-year
mortality was 11.9 (PFT/BLT, AUROC, 0  82; Figure 4B). Repla-
cing TIL levels with counts or ratios of T-lymphocyte subsets did
not improve this model.
DISCUSSION
Patients with HPV-positive OPSCC have significantly better
survival, although the biological reason for this remains unclear
(Adelstein et al, 2009). To reduce therapy-associated morbidity, it
may be possible to de-intensify treatment, particularly as several
studies have shown survival benefit to be independent of therapy
choice (Licitra et al, 2006; Fakhry et al, 2008; Worden et al, 2008;
Adelstein et al, 2009; Lassen et al, 2009; Ang et al, 2010; Dayyani
et al, 2010; Hong et al, 2010b). However, a significant minority of
HPV-positive OPSCC patients experience treatment failure and
have poor outcome; it has been suggested that future clinical
investigations concentrate on this group in order to improve
outcome (and also to avoid treatment de-intensification in these
patients; Adelstein et al, 2009). Currently, there is no widely
accepted strategy for the identification of poor prognosis in HPV-
positive patients before therapy.
A plausible explanation for the differences in survival between
HPV-positive and HPV-negative patients is that virally
driven tumours provoke an adaptive immune response directed
against tumour-expressed viral antigens: immune responses against
the foreign viral antigen are less likely to be suppressed; there is no
central immunological tolerance to confound the immune system’s
attempts to control cancer. HPV-16-specific CD8-positive
T cells have been detected in the blood of HPV-positive OPSCC
patients and, more recently, isolated from tumours, implicating a
role in the anti-tumour response (Albers et al, 2005; Heusinkveld
et al, 2012; Wansom et al, 2012). Several recent studies have
further demonstrated anti-tumour immunity in HPV-positive
OPSCC. Liang et al (2012) found better survival in HPV-positive
patients with seropositivity to E6/E7. Furthermore, infiltration
of HPV-positive HNSCC by PD-1-expressing T lymphocytes
has been shown to be a favourable prognostic factor
(Badoual et al, 2013).
In several solid tumours, quantification of densities of various
T-cell subsets, including CD8þ , CD4þ Treg cells (FoxP3þ
CD4þ ), or subset ratios, have been suggested to improve predictive
power over that of absolute T-cell number (CD3þ ; Gooden et al,
2011). Cytotoxic CD8þ T cells are the principal anti-tumour
effector cells, and their abundance has been shown to be a
predictor of positive outcome in several tumour types, particularly
colorectal cancer, suggesting that the adaptive immune system has
a role in suppressing tumour progression (Galon et al, 2006). Our
analysis of a publicly available HNSCC microarray data set showed
enrichment of genes associated with CD8þ T-cell effector function
in patients with improved survival, arguing that the T cells are not
simply ‘innocent bystanders’ of the biological events in the tumour
but take an active role in tumour recognition.
We conducted this study to examine the effects of HPV status
and TIL levels on survival in OPSCC patients. Similar to other
large studies, HPV-positive tumours were associated with sig-
nificantly improved survival (3-year survival; HPV-positive 82% vs
HPV-negative 56%, Po0.001); pathological and clinical features of
HPV-positive tumours were consistent with these series. The HPV-
positive OPSCC were generally of late stage and were poorly
differentiated (both Po0.001). HPV-positivity inversely correlated
with smoking, and with EGFR expression (all Po0.005). TIL levels
also correlated significantly with the HPV status (Po0.001), with
around 85% of HPV-positive OPSCC tumours containing high or
moderate levels of TIL. Taking into account the array data, this is
likely to reflect an adaptive anti-tumour response as the
mechanism for improved outcome. TIL levels stratified HPV-
positive OPSCC patients into those with good and poor prognosis.
The 3-year survival for HPV-positive/TILhigh tumours was 96%
compared with 76% for HPV-positive/TILmod and 59% for HPV-
positive/TILlow. The HPV-positive/TILlow tumours had similar
survival to HPV-negative tumours (3-year survival, 56%). We also
quantified densities of CD3-, CD4-, CD8-, and FoxP3-positive T
cells and carried out ROC analysis to determine the predictive
value of cell numbers or subset ratios. These more complex
analyses did not outperform the simpler scoring method
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performed on HþE-stained sections. It is possible that lympho-
cyte counts performed on randomly selected TMA cores may not
be representative of the tumour as a whole. However, TMA cell
counts significantly correlated with whole-section TIL levels,
arguing against this (e.g., total (CD3þ ) T-lymphocyte count:
TILlow 42.9, TILmod 60.4, and TILhigh 96.3, Po0.001).
In keeping with previously published studies (Badoual et al,
2006; Bron et al, 2013), we found that infiltration with
Table 2B. HRs for disease-specific death in OPSCC stratified by HPV status
HPV-positive OPSCC, n¼149 HPV-negative OPSCC, n¼121
Univariate HR
(95% CI)
Multivariate
HRa
(95% CI) P-value
Univariate
HR
(95% CI)
Multivariate
HRa
(95% CI) P-value
Age
For each additional year 1.00 (0.97–1.04) 1.02 (0.98–1.06) 0.28 1.02 (0.99–1.04) 1.02 (0.99–1.05) 0.19
Gender
Female 1 1 1 1
Male 1.19 (0.50–2.81) 0.74 (0.26–2.11) 0.58 2.06 (1.06–4.02) 1.70 (0.79–3.64) 0.17
Smoking
Non/ex-smoker/current Smoker o10 pack-years 1 1 1 1
Current smoker 410 pack-years 5.81 (2.38–14.16) 5.80 (2.31–14.54) o0.001 1.37 (0.71–2.64) 1.61 (0.82–3.16) 0.17
Drinking
Non/ex-drinker 1 1 1 1
Current drinker 0.63 (0.23–1.71) 0.29 (0.08–1.04) 0.06 0.68 (0.31–1.49) 0.54 (0.22–1.28) 0.16
Stage
Early (I/II) 1 — — 1 — —
Late (III/IV) 1.93 (0.26–14.27) — — 1.83 (0.99–3.37) — —
T stage
T1/2 1 1 1 1
T3/4 3.42 (1.61–7.28) 3.04 (1.28–7.22) 0.01 1.24 (0.71–2.17) 0.98 (0.52–1.84) 0.94
Nodal metastases
No 1 — — 1 — —
Yes 1.65 (0.39–7.00) — — 2.13 (1.19–3.79) — —
N stage
N0–N2a 1 1 1 1
N2b–N3 2.29 (1.00–5.24) 1.67 (0.67–4.14) 0.27 2.06 (1.20–3.53) 2.15 (1.14–4.06) 0.02
Tumour grade
Well/moderately differentiated 1 1 1 1
Poorly differentiated 0.74 (0.32–1.69) 0.74 (0.30–1.84) 0.52 1.58 (0.92–2.72) 1.50 (0.81–2.81) 0.20
Treatment
Surgery 1 1 1 1
Radiotherapy 1.51 (0.55–4.15) 1.01 (0.30–3.36) 0.99 1.64 (0.87–3.12) 1.50 (0.70–3.22) 0.30
Chemoradiotherapy 0.98 (0.42–2.31) 1.02 (0.39–2.70) 0.96 1.48 (0.76–2.88) 1.18 (0.55–2.57) 0.67
TIL status
TIL high 1 1 1 1
TIL moderate 2.96 (1.11–7.89) 2.47 (0.72–8.50) 0.15 1.39 (0.55–3.48) 1.59 (0.54–4.71) 0.40
TIL low 5.67 (1.96–16.38) 4.86 (1.34–17.60) 0.02 1.71 (0.71–4.13) 2.11 (0.73–6.16) 0.17
EGFR
Negative 1 1 1 1
Positive 1.65 (0.76–3.62) 1.54 (0.63–3.74) 0.34 0.99 (0.53–1.87) 1.31 (0.61–2.83) 0.49
Abbreviations: CI¼ confidence interval; HPV¼ human papillomavirus; HR¼ hazards ratio; OPSCC¼oropharyngeal cancer; TIL¼ tumour-infiltrating lymphocyte.
aMultivariate analysis adjusted for age, T stage, N stage, and smoking status. Patients with no treatment excluded from analysis.
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FoxP3-positive regulatory T cells was associated with improved
survival (Figure 2B). However, we feel that the increased numbers
seen in HPV-positive tumours simply reflect an increase in overall
T-lymphocyte numbers in these tumours. Indeed, the proportion
of Foxp3-positive cells was reduced in HPV-positive tumours,
compared with those that were HPV-negative (Supplementary
Information). Interestingly, TIL levels did not predict for survival
in HPV-negative tumours.
Several studies have reported potential clinical and molecular
predictors for identifying poor prognosis in patients with HPV-
positive tumours. The HPV-positive light- or non-smokers have
the best outcome in OPSCC (Hafkamp et al, 2008; Kumar et al,
2008; Gillison et al, 2012; Sethi et al, 2012). We also found that
HPV-positive current heavy smokers had reduced survival benefit
compared with non-, ex-, or light smokers (3-year survival; HPV-
positive/current heavy smoker 63% vs HPV-positive/non-,
ex-, current light smoker 94%; Supplementary Information). There
was no significant association between heavy smoking and low TIL
levels, arguing against TIL levels acting as a surrogate marker for
heavy smoking. However, it is possible that poor documentation in
retrospective records may be responsible for this lack of
correlation, and this should be examined prospectively. We
calculated LRs to indicate the strength of a marker (maximising
the DR while minimising the FPR). In HPV-positive patients, low
TIL levels and smoking status were the best predictors of
mortality at 3 years (LRs 3  3 and 2  8, respectively). This was
reflected in our prognostic model where, in the ‘training’ set
(UHS patients) only TIL levels, smoking, and T stage were
significant (AUROC analysis 0  87). When this model was
applied to the ‘validation set’ (PFT/BLT cohort), it was found
to be highly predictive (DR 66.7%; FPR 5.6%; LR for 3-year
mortality 11.9). This LR is better than other currently used
predictive tests. For example, the unrehydrated guaiac fecal occult
blood test used in screening for colorectal carcinoma has an LR of
6.4 (DR 64% and FPR 10%) (Allison et al, 2007). The 3-year
survival of low-risk HPV-positive patients (score o 0.945) was
94% compared with 36.8% for those that were classified as
patients with high risk (score 4 0.945, Po0.001).
Ang et al (2010) have suggested a predictive model for HPV-
positive OPSCC where patients who are heavy smokers (410 pack
year history) and have advanced nodal disease (4N2b) are at
increased risk of death. We compared this model with our own,
and calculated both LRs and 3-year survival rates. The LR for the
Ang model in our combined cohort was 4.8 (DR 61.1% and FPR
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Figure 2. Receiver-operating characteristic (ROC) curve for 3-year mortality in HPV-positive OPSCC to determine the predictive value of T-cell
number and/or subtype. (A) Immunochemistry showing representative example of an OPSCC stained with T-cell markers (CD3, pan T cells; CD4,
helper T cells; CD8 cytotoxic T cells; and FoxP3, regulatory T cells). (B) ROC curve for 3-year HPV-positive OPSCC mortality using TIL levels (scored
on HþE-stained section), compared with cell counts following immunochemistry for T-cell subtypes (CD3þ , CD4þ , CD8þ , and Foxp3þ ),
including subtype ratios (CD4:CD8, and Foxp3:CD8). Immunochemical quantification did not outperform the simpler scoring method.
Figure 3. T cell gene-set enrichment in HNSCC. Gene-set enrichment
analysis of publicly available gene sets describing effector CD8þ T
cells. Genes to the left and right of the rank-ordered list are enriched in
HNSCC patients with early (survivalo3 years, mean 16 months) or late
mortality (survival 43 years, mean 49 months), respectively. The rank-
ordered list of genes describing effector CD8þ T cells is shown in
Supplementary Information.
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12.8%; compared with LR¼ 8.6 (DR¼ 70.6% and FPR¼ 8.2%)
using our model) and the 3-year survival was 91.5% for low-risk
patients and 50% for high-risk patients (compared with 94% and
36.8%, respectively, using our model). Clearly, both models have
significant predictive power. Interestingly, we found no association
between TIL levels and nodal status in HPV-positive OPSCC
(P¼ 0.43).
Retrospective studies have intrinsic limitations. In this study,
cases were excluded if there was insufficient archival material for
full pathological and immunochemical analysis. However, demo-
graphics and survival of excluded patients did not differ
significantly from those included in the study (Supplementary
Information). Most patients in this study came from the same
geographical area of England, and we cannot therefore assess the
effect of geographical, genetic, or ethnic influences on our
findings. The number of patients with HPV-positive/TILlow
tumours was relatively small and, thus, any conclusions drawn
must perhaps be treated with some caution. However, this may
simply reflect the fact that the vast majority of HPV-positive
tumours are associated with a prominent immune response.
Similarly, it could be argued that the heterogenous treatments
received by patients in this study complicates the analysis.
However, the uniformly improved survival of HPV-positive
patients, regardless of treatment modality, argues that the reason
for this improved prognosis is related to an intrinsic feature of
these tumours. Prospective analysis of our prognostic model will
be informative, and a multicentre validation study is currently
under development.
Table 3. LRs for 3-year death from OPSCC
Prognostic values for prediction of death from OPSCC at 3 years
HPV-positive OPSCC HPV-negative OPSCC
DR % (21 deaths) FPR % (95 alive) LR DR % (41 deaths) FPR % (53 alive) LR
Age, years
X50 57.1 72.6 0.79 85.4 81.1 1.05
X55 47.6 51.6 0.92 73.2 58.5 1.25
X60 47.6 30.5 1.56 61.0 35.8 1.70
Gender
Male 81.0 66.3 1.22 85.4 62.3 1.37
Smoking
Smoker 410/day 77.8 27.9 2.78 71.4 66.7 1.07
Alcohol
Drinker 72.2 86.1 0.84 75.9 87.5 0.86
Stage
XII, III, IV 100.0 97.9 1.02 97.6 73.6 1.33
XIII, IV 95.2 93.7 1.02 80.5 56.6 1.42
IV 90.5 76.8 1.18 68.3 41.5 1.65
T stage
4T3, T4 57.1 23.4 2.44 43.9 28.8 1.52
Nodal metastases
Yes 95.2 88.4 1.08 78.0 45.3 1.72
N stage
4N2b 76.2 49.5 1.54 58.5 30.2 1.94
Differentiation
Moderate, poor 95.2 98.9 0.96 100.0 98.1 1.02
Poor 66.7 74.7 0.89 53.7 34.0 1.58
EGFR
Positive 66.7 52.6 1.27 78.0 75.5 1.03
TILs
Low, moderate 90.0 46.8 1.92 85.4 84.9 1.01
Low 35.0 10.6 3.30 53.7 41.5 1.29
Abbreviations: DR¼detection rate; FPR¼ false-positive rate; HPV¼ human papillomavirus; LR¼ likelihood ratio; OPSCC¼oropharyngeal cancer; TIL¼ tumour-infiltrating lymphocyte.
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In summary, we show that TIL levels predict for survival in
OPSCC patients. High TIL levels are significantly associated with
HPV status, suggesting that the reason for improved survival in
most HPV-positive OPSCC is the presence of an adaptive host
anti-tumour immune response. Survival in patients with HPV
positive, TILlow tumours, is not significantly different than in those
with HPV-negative disease. A prognostic model based on low TIL
levels, heavy smoking, and late T stage is extremely effective at
identifying a group of HPV-positive patients with poor survival.
Tumour-infiltrating lymphocyte evaluation can be performed
quickly on diagnostic biopsy, and more complex analysis of the
T-cell infiltrate does not improve on the predictive power of the
simpler scoring method. This is an effective tool for identifying
HPV-positive OPSCC patients who are likely to respond poorly to
treatment, and is highly relevant for the clinical and pathological
evaluation of HPV-positive OPSCC.
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